article thumbnail

Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges

Journal of Cardiovascular Electrophysiology

It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. In these conditions, advances in electrophysiology and heart failure physiology are intertwined and are integrated in this review.

article thumbnail

Resynchronization-defibrillation for heart failure shows long-term benefits

Cardiology Update

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). The median follow-up duration for these patients was 7.7

article thumbnail

Heart Hospital of New Mexico at Lovelace Medical Center and GE HealthCare Collaborate to Install the First Allia IGS Pulse Electrophysiology Lab in the United States for Minimally Invasive Cardiovascular Procedures

DAIC

HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations, cardiac catherizations, transcatheter aortic valve replacements, balloon and coronary angioplasties and more. It’s an honor to have the U.S.’s

article thumbnail

An approach to fluoroless radiofrequency atrial fibrillation ablation

Frontiers in Cardiovascular Medicine

It can be associated with reduced quality of life and complications such as heart failure and stroke. Additional advantages include providing electrophysiology lab personnel with a lead-free working environment and avoiding radiation exposure for both patients and physicians.

article thumbnail

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice

Frontiers in Cardiovascular Medicine

Background Sacubitril/valsartan (SacVal) has been shown to improve the prognosis of heart failure; however, whether SacVal reduces the occurrence of atrial fibrillation (AF) in heart failure has not yet been elucidated.

article thumbnail

Ion channel trafficking implications in heart failure

Frontiers in Cardiovascular Medicine

Heart failure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. Among the most serious manifestations associated with HF is arrhythmia due to the electrophysiological changes within the cardiomyocyte.

article thumbnail

Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology

Frontiers in Cardiovascular Medicine

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.